Department of Interventional Radiology, Christie NHS Foundation Trust, Manchester, UK.
J Palliat Care. 2020 Apr;35(2):93-102. doi: 10.1177/0825859719864915. Epub 2019 Aug 25.
Malignant bowel obstruction (MBO) is a common manifestation in patients with advanced intra-abdominal malignancy. It is especially common with bowel or gynecological cancers and produces distressing symptoms, including nausea, vomiting, and pain. Medical management options are less effective than decompressive strategies for symptom control. Surgery is the gold-standard treatment but is unsuitable for most patients with high complication rates. Consensus guidelines recommend nonsurgical management with a venting gastrostomy in those unsuitable for surgery or for whom medical management is ineffective. The aim of this systematic review is to establish the safety and efficacy of percutaneous venting gastrostomy in relieving symptoms of MBO. Twenty-five studies were included in this review comprising 1194 patients. Gastrostomy insertion was successful at first attempt in 91% of cases and reduction in symptoms of nausea and vomiting was reported in 92% of cases. Mean survival following the procedure ranged from 35 to 147 days. Major complications were rare, with most complications classed as minor wound infections or leakage of fluid around the tube. Studies suggest that the presence of ascites is not an absolute contraindication to the insertion of percutaneous venting gastrostomy in patients with MBO; however, these studies lack longitudinal outcomes and complication rates related to this. However, it is reasonable to suggest that ascitic drainage is performed to reduce potential complications. There is a relative lack of good quality robust data on the utilization of percutaneous venting gastrostomy in MBO, but overall, the combination of being a safe and efficacious procedure alongside the known complication profile suggests that it should be considered a suitable management option.
恶性肠梗阻(MBO)是晚期腹腔恶性肿瘤患者的常见表现。它尤其常见于肠道或妇科癌症,并产生令人痛苦的症状,包括恶心、呕吐和疼痛。与减压策略相比,医学管理选择在控制症状方面效果较差。手术是金标准治疗方法,但不适合大多数并发症发生率较高的患者。共识指南建议对不适合手术或医学管理无效的患者进行非手术管理,并采用胃造口术进行减压。本系统评价的目的是确定经皮胃造口术缓解 MBO 症状的安全性和有效性。本综述纳入了 25 项研究,共 1194 例患者。胃造口术首次尝试成功率为 91%,报告恶心和呕吐症状缓解的比例为 92%。术后平均生存时间范围为 35 至 147 天。主要并发症罕见,大多数并发症为轻微的伤口感染或管周液体漏出。研究表明,腹水并不是 MBO 患者行经皮胃造口术的绝对禁忌证;然而,这些研究缺乏与该操作相关的纵向结局和并发症发生率数据。尽管如此,建议在可能的情况下进行腹水引流以降低潜在并发症的风险是合理的。关于经皮胃造口术在 MBO 中的应用,虽然有相对缺乏高质量的可靠数据,但总体而言,由于该操作安全有效,且已知并发症发生率低,因此它应被视为一种合适的治疗选择。